The North America Molecular Diagnostics Market is witnessing significant growth due to rapid technological advancements, rising demand for early disease detection, and increasing prevalence of infectious diseases and cancer. The market was valued at USD 9,500 Million in 2025 and is projected to reach USD 26,700 Million by 2035, expanding at a CAGR of 9.6% from 2024 to 2035.
The economic impact of tariffs on "North America Molecular Diagnostics Market".
Market Growth Drivers
Technological Advancements in Molecular Diagnostics: Companies like Thermo Fisher Scientific and Roche are focusing on advancing molecular diagnostic tools that offer higher accuracy and rapid turnaround times. The integration of automation, artificial intelligence, and next-generation sequencing (NGS) has enabled early disease detection, personalized medicine, and large-scale screening. Thermo Fisher Scientific's latest Ion Torrent Genexus System enables same-day diagnostic results for various infections and cancer markers, ensuring timely clinical intervention and improving prognosis in critical care settings.
Rising Prevalence of Infectious Diseases & Cancer: The increased occurrence of infectious diseases such as COVID-19, HPV, and hepatitis, coupled with growing cancer rates in North America, has propelled demand for precise and rapid molecular testing. Roche's cobas systems for SARS-CoV-2 and HPV are increasingly adopted by hospitals and diagnostic centers to ensure swift detection and isolation, reducing the spread of infectious diseases. This rate of adoption is expected to drive continued growth in the coming decade.
Market Trends
Shift Towards Point-of-Care Testing (POCT): The adoption of portable molecular diagnostic platforms such as Cepheid’s GeneXpert and Abbott’s ID NOW has accelerated. These POCT systems enable rapid on-site testing in physician offices, retail clinics, and remote settings, improving diagnostic access and throughput. Abbott reported a marked increase in ID NOW COVID-19 testing across North America, establishing POCT as a mainstay for infectious disease management.
Expansion of Liquid Biopsy Applications: Leading players like Guardant Health and Illumina are driving the expansion of liquid biopsies for cancer detection, monitoring, and recurrence prediction. The non-invasive nature and ability to repeatedly monitor patients have made liquid biopsy a promising trend. In 2023, Guardant Health launched its Shield test for early colorectal cancer detection, and uptake in U.S. laboratories has increased substantially, reflecting the growing demand for minimally invasive diagnostics.
Market Opportunity
Expansion into Personalized Medicine: Companies like Illumina and QIAGEN are leveraging genomics-driven molecular diagnostics to create personalized medicine solutions, including companion diagnostics, which are expected to see robust growth with the increasing availability of targeted therapeutics.
Growth in Home-based Diagnostic Solutions: There is ample opportunity for companies such as Cue Health and Lucira Health to develop molecular diagnostics platforms for home use, especially for infectious disease testing, empowering consumers and expanding reach beyond traditional healthcare settings.
North America Molecular Diagnostics Market Revenue (USD Million), 2020-2035
The revenue for the North America Molecular Diagnostics Market has shown robust growth from 2020 to 2025, driven primarily by increased test utilization during the COVID-19 pandemic and ongoing adoption of advanced molecular diagnostic platforms. The data indicates a slight leveling-off post-pandemic as the market stabilizes and growth is subsequently sustained by broader applications in oncology, genetics, and point-of-care testing. By 2035, the market is forecasted to reach USD 26,700 Million, reflecting technological advances and expansion into new clinical areas.
North America Molecular Diagnostics Market by Region Share (%), 2025
In 2025, the United States dominates the North America Molecular Diagnostics Market with 74% of the regional market share, attributed to its advanced healthcare infrastructure, high R&D spending, and extensive adoption of novel diagnostic technologies. Canada follows with a 19% share driven by public health initiatives and growing investment in precision medicine. Mexico holds a 5% share, experiencing steady growth as access to molecular diagnostics improves. Other smaller North American countries collectively account for 2%. This regional split highlights the market concentration in the U.S. while reflecting emerging opportunities in Canada and Mexico.
Recent Developments
In March 2024, Roche received FDA approval for its cobas Malaria test for use in blood screening laboratories in the U.S., marking a significant step towards safer blood transfusions and enhancing testing capabilities for blood banks nationwide. The new test expands Roche's cobas suite of molecular diagnostics and underlines the company's continued leadership in infectious disease diagnostics in North America.
In May 2024, Abbott launched the ID NOW STI test, a rapid molecular test for sexually transmitted infections (STIs), featuring a 13-minute turnaround time at point-of-care. The new diagnostic gained immediate adoption across urgent care and sexual health clinics. The company also reported partnership agreements with major U.S. retail pharmacy networks to deploy the solution for improved community access to critical diagnostics.
In February 2024, Thermo Fisher Scientific announced a collaboration with Mayo Clinic to advance NGS-based diagnostic tests for rare genetic diseases. The partnership aims to accelerate the validation and rollout of highly accurate molecular panels for clinical genetics, with pilot programs already underway in select academic centers. This collaboration strengthens Thermo Fisher's position in precision diagnostics and expands NGS accessibility in North America.
Press Releases